Merus N.V. (MRUS)
- Previous Close
41.60 - Open
49.69 - Bid 55.03 x 300
- Ask 55.36 x 200
- Day's Range
49.44 - 57.45 - 52 Week Range
33.19 - 61.28 - Volume
7,883,815 - Avg. Volume
951,514 - Market Cap (intraday)
3.816B - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-4.16 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
87.67
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
www.merus.nlRecent News: MRUS
View More
Performance Overview: MRUS
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRUS
View MoreValuation Measures
Market Cap
3.82B
Enterprise Value
3.37B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
67.45
Price/Book (mrq)
6.40
Enterprise Value/Revenue
61.54
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.61%
Return on Equity (ttm)
-58.66%
Revenue (ttm)
54.73M
Net Income Avi to Common (ttm)
-277.34M
Diluted EPS (ttm)
-4.16
Balance Sheet and Cash Flow
Total Cash (mrq)
458.32M
Total Debt/Equity (mrq)
1.65%
Levered Free Cash Flow (ttm)
-112.4M
Research Analysis: MRUS
View MoreResearch Reports: MRUS
View MoreDaily – Vickers Top Buyers & Sellers for 10/12/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/11/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/02/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/25/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.